Guang He Sheng Chuang was funded by Yongrun Investment and established in 2022 in the Biomedical Science Park in Zhubei City, Hsinchu County. It is a biomedical startup focusing on nucleic acid biomarker technology. The founding team consists of three PhDs from different fields (molecular biology, nanotechnology, and chemical engineering) and an entrepreneur from the technology industry. Guang He Sheng Chuang possesses core technology capabilities, including independently developed nano-sensing materials, nano-carbon probe combination reagents, and biochemical analysis and detection software. The greatest difference between this technology and traditional nucleic acid detection methods is that it directly detects and quantifies nucleic acid molecules without the need for PCR amplification, thereby significantly shortening operation time and improving accuracy and sensitivity. The company's vision is to reveal individual disease and health trends through nucleic acid biomarker technology, guide treatment directions, and achieve the goals of precision medicine and preventive medicine, which can be further applied to genomic research to contribute to human health and society.
(The content above was translated by AI.)